{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:17:51Z","timestamp":1778591871620,"version":"3.51.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009148","name":"Queen Mary University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009148","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cefiderocol is a recently licensed novel siderophore-conjugated cephalosporin stable to hydrolysis by serine and MBLs. It has been successfully used to treat Enterobacterales infections and is approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the compassionate use of cefiderocol and clinical outcome in a case of prosthetic joint infection due to MDR Acinetobacter baumannii.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>This case study follows a 66-year-old woman who sustained an open fracture of the left distal humerus in Pakistan. She underwent open reduction and internal fixation and on return to the UK presented to hospital with a discharging surgical wound.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Debridement of her wound cultured NDM carbapenemase-producing A. baumannii susceptible to colistin, tobramycin and tigecycline only. She developed vomiting with acute kidney injury with colistin and tigecycline. Antimicrobial efficacy of cefiderocol was predicted from in vitro and in vivo susceptibility tests. A successful request was made to Shionogi for compassionate use of cefiderocol, which was added to tigecycline. Cefiderocol was well tolerated with no toxicity and improved renal function. In total she received 25\u2009days of cefiderocol and continued on tigecycline for a further 6\u2009weeks in the community. She has well-healed wounds and good range of elbow movement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cefiderocol\u2019s novel mode of cell entry is effective against MDR Gram-negative bacteria with reduced toxicity compared with other last line antibiotics. Our case demonstrates that cefiderocol may be useful as therapy for patients with limited treatment options due to antimicrobial resistance. The prescribing information for cefiderocol is available at: https:\/\/shionogi-eu-content.com\/gb\/fetcroja\/pi.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlab055","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T19:09:16Z","timestamp":1617390556000},"page":"i21-i24","source":"Crossref","is-referenced-by-count":18,"title":["Compassionate use of cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii<\/i> prosthetic joint infection"],"prefix":"10.1093","volume":"3","author":[{"given":"Diana A","family":"Mabayoje","sequence":"first","affiliation":[{"name":"Division of Infection, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caoimhe","family":"NicFhogartaigh","sequence":"additional","affiliation":[{"name":"Division of Infection, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benny P","family":"Cherian","sequence":"additional","affiliation":[{"name":"Division of Infection, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Gie Meiqi","family":"Tan","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-5224","authenticated-orcid":false,"given":"David W","family":"Wareham","sequence":"additional","affiliation":[{"name":"Division of Infection, Barts Health NHS Trust, London, UK"},{"name":"Antimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"2021082617410086900_dlab055-B1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fmicb.2019.00930","article-title":"Comparative analysis of the two Acinetobacter baumannii multilocus sequence typing (MLST) schemes","volume":"10","author":"Gaiarsa","year":"2019","journal-title":"Front Microbiol"},{"key":"2021082617410086900_dlab055-B2","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1128\/AAC.00230-11","article-title":"In-vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection","volume":"55","author":"Hornsey","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021082617410086900_dlab055-B3","year":"2020"},{"key":"2021082617410086900_dlab055-B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijantimicag.2009.10.024","article-title":"Multidrug resistant Acinetobacter baumannii: mechanisms of virulence and resistance","volume":"35","author":"Gordon","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2021082617410086900_dlab055-B5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/590568","article-title":"Acinetobacter baumannii skin and soft-tissue infection associated with war trauma","volume":"47","author":"Sebeny","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021082617410086900_dlab055-B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2012.09.008","article-title":"Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages","volume":"41","author":"Zarrilli","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2021082617410086900_dlab055-B7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jgar.2020.01.001","article-title":"Dissemination of blaOXA-23-harbouring carbapenem-resistant Acinetobacter baumannii clones in Pakistan","volume":"21","author":"Khurshid","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2021082617410086900_dlab055-B8","first-page":"23","article-title":"Prevalence of multidrug resistant Acinetobacter baumannii in hospitalized patients in Lahore","volume":"2","author":"Shamim","year":"2015","journal-title":"Pakistan. Pakistan J Mol Med"},{"key":"2021082617410086900_dlab055-B9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1099\/jmm.0.063925-0","article-title":"Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in Pakistan","volume":"63","author":"Hasan","year":"2014","journal-title":"J Med Microbiol"},{"key":"2021082617410086900_dlab055-B10","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69 Suppl 7","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021082617410086900_dlab055-B11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"2021082617410086900_dlab055-B12","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria","volume":"69 Suppl 7","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021082617410086900_dlab055-B13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021082617410086900_dlab055-B14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021082617410086900_dlab055-B15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1473-3099(18)30721-7","article-title":"Cefiderocol for treatment of complicated urinary tract infections","volume":"19","author":"Portsmouth","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021082617410086900_dlab055-B16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2021082617410086900_dlab055-B17","doi-asserted-by":"crossref","first-page":"e01872","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021082617410086900_dlab055-B18","doi-asserted-by":"crossref","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: successful rescue therapy of extensively drug-resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021082617410086900_dlab055-B19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2021082617410086900_dlab055-B20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2021082617410086900_dlab055-B21","doi-asserted-by":"crossref","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: real-world experience from a case series and review of the literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/Supplement_1\/i21\/39990384\/dlab055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/Supplement_1\/i21\/39990384\/dlab055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T17:42:18Z","timestamp":1629999738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/3\/Supplement_1\/i21\/6299849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":21,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab055","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,6,1]]}}}